Interpretation of Key Points in 2024 Chinese Expert Consensus on EGFR Exon 20 Insertion Mutations in Non-Small Cell Lung Cancer
The Chinese Society of Clinical Oncology (CSCO) NSCLC Expert Committee has updated the 2023 Chinese expert consensus in light of the growing understanding of epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations in non-small cell lung cancer (NSCLC) and the emergence of new c...
Saved in:
| Main Authors: | Xuanhong JIN, Fei ZHOU |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Magazine House of Cancer Research on Prevention and Treatment
2025-06-01
|
| Series: | Zhongliu Fangzhi Yanjiu |
| Subjects: | |
| Online Access: | http://www.zlfzyj.com/cn/article/doi/10.3971/j.issn.1000-8578.2025.25.0120 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Real-world pharmacovigilance analysis unveils the toxicity profile of amivantamab targeting EGFR exon 20 insertion mutations in non-small cell lung cancer
by: Jing Zhang, et al.
Published: (2025-02-01) -
Amivantamab versus standard therapies among patients with advanced non-small cell lung cancer and epidermal growth factor receptor exon 20 insertion mutations after platinum-based therapy in China
by: Lan Shen, et al.
Published: (2025-08-01) -
Molecular characteristics and responses to EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients with EGFR exon 19 insertions
by: Yang Li, et al.
Published: (2025-04-01) -
Patterns of Treatment and Real‐World Outcomes of Patients With Non‐small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations Receiving Mobocertinib: The EXTRACT Study
by: Geoffrey Liu, et al.
Published: (2025-02-01) -
Unraveling Survival Determinants in Patients with Advanced Non-Small-Cell Lung Cancer with <i>EGFR</i> Exon 20 Insertions
by: Kung-Yang Wang, et al.
Published: (2025-03-01)